Newsletter : Featured Clinical Trial
Clinical Trial to Study Whether Coenzyme Q10 May Help Slow Functional Decline in HD Patients
Researchers with The Huntington Study Group (HSG) recently launched a Phase III clinical trial to determine the effect of Coenzyme Q10 on individuals with Huntington's Disease (HD). The study, funded by the NIH's National Institute of Neurological Disorders and Stroke, will follow 608 patients for five years to evaluate the effects of high doses of CoQ10 in slowing functional decline in Huntington's disease patients. The study also will examine the long-term safety of prolonged exposure to extremely high doses of CoQ10 (2,400 mg per day). Huntington's disease is a genetic, progressive brain disorder that causes uncontrolled movements, cognitive difficulties and emotional disturbances.
The HSG, a non-profit group of clinical investigators, began enrolling patients into the double-blind, placebo-controlled study on March 19, 2008 in centers across the United States, Canada and Australia.
"This is an extremely important trial, and Kaneka Nutrients is proud to be the sole source of CoQ10 being used in the study," said Dr. Robert Barry, Director of Scientific Affairs for Kaneka Nutrients L.P.'s U.S. Operations. "We're eager to see the trial results since they potentially represent hope for a better quality of life for patients suffering from this debilitating disease."
Researchers with The Huntington Study Group (HSG) recently launched a Phase III clinical trial to determine the effect of Coenzyme Q10 on individuals with Huntington's Disease (HD). The study, funded by the NIH's National Institute of Neurological Disorders and Stroke, will follow 608 patients for five years to evaluate the effects of high doses of CoQ10 in slowing functional decline in Huntington's disease patients. The study also will examine the long-term safety of prolonged exposure to extremely high doses of CoQ10 (2,400 mg per day). Huntington's disease is a genetic, progressive brain disorder that causes uncontrolled movements, cognitive difficulties and emotional disturbances.
The HSG, a non-profit group of clinical investigators, began enrolling patients into the double-blind, placebo-controlled study on March 19, 2008 in centers across the United States, Canada and Australia.
"This is an extremely important trial, and Kaneka Nutrients is proud to be the sole source of CoQ10 being used in the study," said Dr. Robert Barry, Director of Scientific Affairs for Kaneka Nutrients L.P.'s U.S. Operations. "We're eager to see the trial results since they potentially represent hope for a better quality of life for patients suffering from this debilitating disease."
